CFTR and cystic fibrosis: Even with the large Archer CF assay second-tier panel, retrospective analysis had previously demonstrated that approximately 8% of alleles in confirmed NYS CF cases were only detected by full bioinformatic analysis, verifying the diverse NYS CFTR variant spectrum, and demonstrating the utility of comprehensive third-tier analysis.